Is urinary soluble Fas an independent predictor of non-muscle-invasive bladder cancer? A prospective chart study

Urologia Internationalis

Volumn 91, Issue 4, 2013, Pages 456-461

  Yang, Huixiang ^a   Li, Huijie ^b   Wang, Zhenchao ^d   Gao, Jing ^c   Guo, Yong ^a  

^a FIRST HOSPITAL OF SHIJIAZHUANG   (China)

^b Department of Oncology ^*  (China)

^c Computer Network Center ^*  (China)

^d CHENGDE MEDICAL COLLEGE   (China)

Author keywords

European Organisation for Research and Treatment of Cancer; Non muscle invasive bladder cancer; Prognosis; Soluble Fas; Tumor marker; Urine

Indexed keywords

FAS LIGAND; SOLUBLE FAS PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FAS ANTIGEN; PIRARUBICIN;

ADULT; AGED; CANCER PROGNOSIS; CANCER RISK; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NON MUSCLE INVASIVE BLADDER CANCER; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RECURRENT DISEASE; REVIEW; TUMOR RECURRENCE; URINALYSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; RECURRENCE FREE SURVIVAL; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84890041154     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000350752     Document Type: Review

References (20)

1. McConkey DJ, Lee S, Choi W, Tran M, Majewski T, Lee S, Siefker-Radtke A, Dinney C, Czerniak B: Molecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progression. Urol Oncol 2010; 28: 429-440.
2. van Rhijn BW, Zuiverloon TC, Vis AN, Radvanyi F, van Leenders GJ, Ooms BC, Kirkels WJ, Lockwood GA, Boeve ER, Jobsis AC, Zwarthoff EC, van der Kwast TH: Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol 2010; 58: 433-441.
3. Witjes JA, Hendricksen K: Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur Urol 2008; 53: 45-52.
4. Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J, Reich O, Roupret M, Shariat SF, Zlotta AR: Urine markers for detection and surveillance of non-muscleinvasive bladder cancer. Eur Urol 2011; 60: 484-492.
5. Ulukaya E, Acilan C, Yilmaz M, Yilmaztepe-Oral A, Ari F, Zik B, Ursavas A, Tokullugil AH: sFas levels increase in response to cisplatin-based chemotherapy in lung cancer patients. Cell Biochem Funct 2010; 28: 565-570.
6. Cascino I, Papoff G, Eramo A, Ruberti G: Soluble Fas/Apo-1 splicing variants and apoptosis. Front Biosci 1996; 1:d12-d18.
7. Yang J, Epling-Burnette PK, Painter JS, Zou J, Bai F, Wei S, Loughran TP Jr: Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-largegranular lymphocyte leukemia. Blood 2008; 111: 1610-1616.
8. Lin Y, Kikuchi S, Yagyu K, Ishibashi T, Kurosawa M, Ito Y, Watanabe Y, Inaba Y, Tajima K, Nakachi K, Tamakoshi A; JACC Study Group: Serum soluble fas levels and superoxide dismutase activity and the risk of death from pancreatic cancer: a nested case-control study within the Japanese Collaborative Cohort Study. Asian Pac J Cancer Prev 2009; 10(suppl):81-85.
9. Boroumand-Noughabi S, Sima HR, Ghaffarzadehgan K, Jafarzadeh M, Raziee HR, Hosseinnezhad H, Moaven O, Rajabi-Mashhadi MT, Azarian AA, Mashhadinejad M, Tavakkol-Afshari J: Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma. BMC Cancer 2010; 10: 275.
10. Mizutani Y, Yoshida O, Ukimura O, Kawauchi A, Bonavida B, Miki T: Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer. Cancer Biother Radiopharm 2002; 17: 563-567.
11. Perabo FG, Mattes RH, Wirger A, Steiner G, Kamp S, Schmidt D, Pegelow K, von Ruecker A, Muller SC: Soluble Fas and Fas-ligand in bladder cancer in vitro and in vivo. Urol Oncol 2001; 6: 163-169.
12. Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI, Shariat SF: Soluble Fas-a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer 2006; 106: 1701-1707.
13. Ganas V, Kalaitzis C, Sountoulides P, Giannakopoulos S, Touloupidis S: Predictive values of urinary bladder tumor markers survivin and soluble-Fas comparison with cystoscopy and bladder tumor antigen. Minerva Urol Nefrol 2012; 64: 279-285.
14. Greene FL: The American Joint Committee on Cancer: updating the strategies in cancer staging. Bull Am Coll Surg 2002; 87: 13-15.
15. Bol MG, Baak JP, Buhr-Wildhagen S, Kruse AJ, Kjellevold KH, Janssen EA, Mestad O, Ogreid P: Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol 2003; 169: 1291-1294.
16. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J; European Association of Urology (EAU): EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54: 303-314.
17. Botteman MF, Pashos CL, Hauser RS, Laskin BL, Redaelli A: Quality of life aspects of bladder cancer: a review of the literature. Qual Life Res 2003; 12: 675-688.
18. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466-475; discussion 475-477.
19. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, Rouprêt M; European Association of Urology (EAU): EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011; 59: 997-1008.
20. Cheng L, Zhang S, MacLennan GT, Williamson SR, Lopez-Beltran A, Montironi R: Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol 2011; 42: 455-481.